Influence des traitements sur le risque cardiovasculaire de la polyarthrite rhumatoïde

The relevant increase in cardiovascular risk associated with rheumatoid arthritis (RA) has been well established over the last decade. The current update is focused on the effects of synthetic treatments, as well as biological medicines, on both the cardiovascular risk and the RA-associated enhanced morbidity and mortality. In addition, the impact of non-steroidal anti-inflammatory drugs and corticosteroids on the RA-associated cardiovascular risk is briefly recalled. Lastly, the clinical management of dyslipidemia, as outlined in the recent HAS guidelines, is presented in addition to the benefit of long-term statin therapy.